A M ATTR of Time

Managing ATTR Cardiac Amyloidosis*:
Reviewing Guidance and Evidence to Help
Optimize Patient Outcomes

Featuring:

• Updated expert consensus guidance on diagnosing and managing ATTR-CM
• Primary and Post-Hoc analyses from ATTR-ACT, including outcomes by disease stage
• Patient case illustrating a framework for ongoing disease management

*Also known as transthyretin amyloid cardiomyopathy (ATTR-CM).
ATTR-CM=transthyretin amyloid cardiomyopathy; ATTR-ACT=Tafamidis in Transthyretin Cardiomyopathy Clinical Trial

Next Program:
Thursday, 23 April 2026 - 12:15 pm PST

(Note that the webinar cannot be viewed on a mobile device, please use a computer or tablet.)

Click below to learn more about the speakers and register to attend a program virtually.

Indication

Important Safety Information

Indication

VYNDAQEL® (tafamidis meglumine) and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. Please see Full Prescribing Information including Patient Information.
Adverse Reactions
In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.

Specific Populations

Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.

Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.